Free Trial

Biogen (BIIB) News Today

$214.41
-4.32 (-1.98%)
(As of 05:27 PM ET)
BIIB Jun 2024 350.000 put
Biogen (NASDAQ:BIIB) Receives Outperform Rating from Royal Bank of Canada
Royal Bank of Canada restated an "outperform" rating and issued a $317.00 price objective on shares of Biogen in a report on Wednesday.
BIIB Jan 2026 120.000 call
BIIB Jun 2024 220.000 call
Eaton Financial Holdings Company LLC Purchases Shares of 5,062 Biogen Inc. (NASDAQ:BIIB)
Eaton Financial Holdings Company LLC bought a new stake in Biogen Inc. (NASDAQ:BIIB - Free Report) in the 4th quarter, according to its most recent 13F filing with the SEC. The firm bought 5,062 shares of the biotechnology company's stock, valued at approximately $1,310,000. Other institutional inv
The Biggest Biotechnology Company in Europe
The Biggest Publicly Traded Biotech Company
Robeco Institutional Asset Management B.V. Sells 180,219 Shares of Biogen Inc. (NASDAQ:BIIB)
Robeco Institutional Asset Management B.V. trimmed its position in Biogen Inc. (NASDAQ:BIIB - Free Report) by 52.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 161,591 shares of the biotechnology company'
Biogen Inc. (NASDAQ:BIIB) Stock Holdings Raised by Primecap Management Co. CA
Primecap Management Co. CA raised its position in shares of Biogen Inc. (NASDAQ:BIIB - Free Report) by 1.6% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 16,264,481 shares of the biotechnology comp
Biogen (NASDAQ:BIIB) Earns "Buy" Rating from HC Wainwright
Franklin Resources Inc. Trims Stock Holdings in Biogen Inc. (NASDAQ:BIIB)
Franklin Resources Inc. trimmed its position in Biogen Inc. (NASDAQ:BIIB - Free Report) by 20.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 498,349 shares of the biotechnology company's stock afte
Biogen (NASDAQ:BIIB) Stock Rating Reaffirmed by HC Wainwright
HC Wainwright reiterated a "buy" rating and issued a $300.00 price objective on shares of Biogen in a research report on Thursday.
Deep Dive Into Biogen Stock: Analyst Perspectives (17 Ratings)
Needham & Company LLC Reiterates "Buy" Rating for Biogen (NASDAQ:BIIB)
Needham & Company LLC reissued a "buy" rating and set a $294.00 price objective on shares of Biogen in a research note on Wednesday.
Biogen Inc. (NASDAQ:BIIB) Shares Sold by Beacon Pointe Advisors LLC
Beacon Pointe Advisors LLC reduced its position in Biogen Inc. (NASDAQ:BIIB - Free Report) by 75.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,542 shares of the biotechnology company's stock after selling 13,614 shares d
Biogen Inc. (NASDAQ:BIIB) Holdings Reduced by Beutel Goodman & Co Ltd.
Beutel Goodman & Co Ltd. reduced its stake in Biogen Inc. (NASDAQ:BIIB - Free Report) by 0.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 995,456 shares of the biotechnology company's stock after selling 3
Biogen Inc. (NASDAQ:BIIB) Shares Sold by BNP Paribas Asset Management Holding S.A.
BNP Paribas Asset Management Holding S.A. trimmed its holdings in shares of Biogen Inc. (NASDAQ:BIIB - Free Report) by 32.1% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 448,432 shares of the biotechnology company's stock after selling 212,114
Panagora Asset Management Inc. Has $3.98 Million Stock Holdings in Biogen Inc. (NASDAQ:BIIB)
Panagora Asset Management Inc. lessened its stake in Biogen Inc. (NASDAQ:BIIB - Free Report) by 87.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 15,360 shares of the biotechnology company's stock after selli
Ionis, Biogen Down on Ending Development of ALS Drug
Biogen (NASDAQ:BIIB) Given "Buy" Rating at Truist Financial
Truist Financial reaffirmed a "buy" rating and set a $340.00 price objective on shares of Biogen in a research report on Thursday.
Get Biogen News Delivered to You Automatically

Sign up to receive the latest news and ratings for BIIB and its competitors with MarketBeat's FREE daily newsletter.

Biden replacement revealed? (Ad)

A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.

See his shocking evidence in this new report

BIIB Media Mentions By Week

BIIB Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

BIIB
News Sentiment

0.50

0.78

Average
Medical
News Sentiment

BIIB News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

BIIB Articles
This Week

36

17

BIIB Articles
Average Week

Get Biogen News Delivered to You Automatically

Sign up to receive the latest news and ratings for BIIB and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:BIIB) was last updated on 5/29/2024 by MarketBeat.com Staff

From Our Partners